Resources
Covid 19 Information
A section dedicated to information on pharmacovigilance of medicinal products used to treat and prevent COVID-19 (coronavirus).
The section is divided into two parts: one part relating to links to national and international institutional websites on SARS-CoV-2 (COVID-19) and another part relating to important research documents and initiatives from ISoP members and others.
This page will be regularly updated.
COVID-19 Resources
Here you will find some links to national and international institutional websites and published papers on COVID-19. Stay informed with the latest clinical research and resources.
World Health Organization
Visit LinkCenters for Disease Control and Prevention
Visit LinkNational Institute of Health
Visit LinkEuropean Medicines Agency
Visit LinkCOVID-19 data sources (Knowledge Portal on Innovation and Access to Medicines)
Visit LinkThe Lancet
Visit LinkThe New England Journal Of Medicine
Visit LinkOxford Covid-19 Evidence service
Visit LinkThe Royal College of Obstetricians and Gynaecologists (RCOG)
Visit LinkItalian Society of Pharmacology – English COVID-19 section
Visit LinkJAMA Network
Visit LinkInternational Union of Pharmacology and Clinical Pharmacology (IUPHAR)
Visit LinkNIPH-Live map of COVID-19 evidence
Visit LinkSpringer Nature
Visit LinkThe International Coalition of Medicines Regulatory Authorities (ICMRA)
Visit LinkSafety Monitoring Using WHO Global Database of Individual Case Safety Reports (ICSRs). Descriptive analysis of spontaneous report from VigiBase
Visit LinkIndian Council of Medical Research updated ethical guidance for biomedical and health research
Visit LinkAfrican Vaccine Regulatory Forum (AVAREF) tools for Processing clinical trial applications by Ethics Committees and National Regulatory Authorities in Africa
Visit LinkLandscape of COVID-19 candidate vaccines/Draft
Visit LinkWHO Covid-19 vaccine safety manual
Visit LinkThe Vaccine Centre & London School of Hygiene & Tropical Medicine
Visit LinkNZ Pharmacovigilance Centre Project encouraging feedback on COVID-19 Medication Safety Challenges in NZ
Visit LinkJohns Hopkins University-Coronavirus Resource Center
Visit LinkISoP Member Papers and initiatives
ISoP colleagues in the North American Chapter of ISoP (NASoP) and the Italian Society of Pharmacology (SIF) are working on proposals to monitor the safety of medicines and vaccines to treat and prevent COVID-19. Here you will find also important research documents and initiatives from ISoP members and others.
Official statement of the section of Clinical Pharmacology of the Italian Society of Pharmacology on the use of ACE- inhibitors or angiotensin receptor blockers in COVID-19 infection with commentary.
SIF
Official Statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary.
SIF
Simplified description of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Viral lifecycle and drug repurposing strategies.
View PaperBenefit-Risk evaluation for Remdesivir in COVID-19.
Drug Safety Research Unit
The challenging times and opportunities for pharmacovigilance in Africa during the COVID-19 pandemic.
African Chapter of ISoP / Executive Committee
ISoP infographic ‘Using Medicines Safely during the COVID-19 pandemic’. This infographic is aimed at patients and caregivers – feel free to display it in hospitals, clinics, pharmacies and any other public spaces appropriate to where medicines are obtained in your country.
ISoP
Posibles terapias para COVID-19: revision narrativa de seguridad I. Cloroquina / hidroxicloroquina y azitromicina.
Raquel Herrera Comoglio
Convalescent plasma in treatment of COVID-19 A review of evidence for a living systematic benefit-risk assessment.
Drug Safety Research Unit
Systematic benefit-risk assessment for the use of CQ or HCQ as a treatment for COVID-19.
Drug Safety Research Unit
Postmarketing studies can they provide a safety net for COVID-19 vaccines in the UK.
Drug Safety Research Unit
How To Investigate A Serious Adverse Event Reporting during Clinical Trial for a COVID-19 vaccine.
Drug Safety Research Unit
What is the difference between observed association and causal association, signals and evidence.
Drug Safety Research Unit
Lopinavir Ritonavir in the Treatment of COVID-19 A dynamic systemative benefit risk assessment.
Drug Safety Research Unit
DSRU Global Pharmacovigilance Observatory. Dissemination of evidence reviews about the safety of medicines and vaccines from around the world.
Drug Safety Research Unit
Challenges for drug repurposing in the COVID-19 pandemic era.
Drug Safety Research Unit
COVID vaccines – Questions & Answers from ISoP Israel Task Force.
ISoP Israel Chapter
ISoP infographic ‘COVID-19 Vaccine Safety’. This infographic is aimed at patients and caregivers – feel free to display it in hospitals, clinics, pharmacies and any other public spaces appropriate to where medicines are obtained in your country.
ISoP
Guide For the development of pharmacovigilance & Guideline On good pharmacovigilance practices in the context SARS-CoV-2 (COVID-19).
Colombian Pharmacovigilance Association (ACFV)
Disclaimer
The contents of this page are intended for purely informational purposes (the list is not exhaustive). Updated Jan 2022.